HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Over The Counter 9 May 2022: The Landscape Of Naloxone Access With HRT’s Michael Hufford

Executive Summary

In this episode, HBW Insight speaks to Michael Hufford, co-founder and CEO of Harm Reduction Therapeutics about the inaccessibility in the US of naloxone, a life-saving opioid overdose antidote. Hufford unpacks the history of naloxone access and explains why standing orders aren’t as helpful as they seem. We also explore the incentives for companies currently producing prescription naloxone to make the switch to OTC status, and why many of them have chosen not to. While the financial incentive may not be there, the public health need is dire, and Hufford explains the importance of harm reduction groups and non-profit pharmaceutical companies for getting naloxone into the hands of those who need it the most.

Further Reading

HRT Reports 'Remarkable Achievement' In OTC Naloxone Phase 1 Clinical Trial Results

OTC Naloxone May Get Another Push From US FDA As Agency Prepar es Novel Switch Proposed Rule

Drivers For Allowing OTC Naloxone In US Include Social Justice As Well As Public Health Need

OTC Naloxone Nasal Spray Biocompatibility Study Funded In US From Purdue Pharma Bankruptcy 

FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals

Further Listening

Check out this episode of the Pink Sheet Podcast, where Pink Sheet and HBW Insight reporters and editors discuss comments that FDA commissioner Robert Califf made implying that the FDA might step in to urge manufacturers to pursue an Rx-to-OTC switch of naloxone.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Over The Counter Theme Music:

Modern Chillout by penguinmusic

Copyright 2021 Licensed under a commercial Pixabay License.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts